Browse the evidence

Mutations in the AMPK gamma-2 subunit (PRKAG2) cause a gain-of-function effect leading to excessive glycogen storage and cardiac hypertrophy.

For individuals with PRKAG2 mutations, excessive AMPK activity leads to dangerous glycogen accumulation in the heart. This highlights the importance of precise regulation of energy-sensing pathways in cardiac tissue.

Platelet-rich plasma (PRP) injections show no significant positive effect on muscle injury recovery compared to placebo in randomized clinical trials, despite widespread clinical use.

Do not expect PRP injections to significantly improve your muscle injury recovery compared to standard care or placebo. Current clinical trials do not support its efficacy for this specific use case.

Leptin signaling in POMC neurons is essential for energy homeostasis, and leptin deficiency causes obesity, which can be corrected by leptin administration.

Leptin is crucial for weight regulation, but it only works as a treatment for those with a specific genetic deficiency. It is not a general weight-loss drug for the majority of people with obesity.

Adipokine-based therapies face major biological roadblocks including lack of efficacy in humans despite rodent success, incomplete understanding of mechanisms, and adverse side effects.

Developing new obesity drugs based on adipokines is difficult because success in mice often fails in humans, mechanisms are often unknown, and side effects are common. This makes the drug development process long, expensive, and prone to failure.

Exogenous leptin therapy is effective in treating obesity and metabolic disorders only in individuals with congenital leptin deficiency or generalized lipodystrophy, but is ineffective for the majority of people with common obesity.

Leptin therapy is not a weight-loss drug for the general public. It is a life-saving treatment for rare genetic conditions where the body produces no leptin. For most people with obesity, adding more leptin does not work because the body has stopped listening to it.

The hyperinsulinemic euglycemic clamp is the gold standard method for quantifying insulin sensitivity in vivo, offering high reproducibility and the ability to distinguish hepatic from peripheral resistance.

The hyperinsulinemic euglycemic clamp is the most accurate way to measure insulin sensitivity and is the research gold standard. However, due to its complexity and cost, it is reserved for research. Clinicians use simpler, less accurate surrogate tests for routine patient care.

Dual-PPARα/γ agonists (glitazars) like muraglitazar, tesaglitazar, and aleglitazar have largely failed in clinical development for type 2 diabetes and cardiovascular disease due to severe safety concerns, including heart failure, renal dysfunction, and increased mortality.

Do not seek out dual-PPAR agonists like muraglitazar or aleglitazar. These drugs were developed for diabetes and heart health but were withdrawn from the market because they caused serious side effects like heart failure and kidney problems. Stick to established treatments with proven safety profiles.

Olive oil polyphenols do NOT currently have sufficient evidence to support a health claim for maintaining normal blood HDL-cholesterol concentrations, despite some studies showing increased HDL levels.

Don't rely on olive oil to boost your HDL cholesterol as a primary heart health strategy. While some studies show HDL levels go up, regulators say this isn't a proven cause-and-effect benefit. Focus instead on the proven benefit: protecting your blood lipids from oxidation by using high-polyphenol olive oil as part of a healthy diet.

Daily subcutaneous administration of recombinant human leptin normalizes hyperphagia and induces significant weight loss in patients with congenital leptin deficiency.

If you have been diagnosed with congenital leptin deficiency, daily injections of recombinant leptin are the standard of care and can significantly reduce hunger and promote weight loss. This treatment is not effective for typical obesity where leptin levels are already high.

Orexin deficiency causes narcolepsy, characterized by excessive daytime sleepiness, cataplexy, and fragmented sleep-wake cycles, due to the loss of orexin neurons in the hypothalamus.

If you experience excessive daytime sleepiness, cataplexy, or fragmented sleep, consult a specialist. Narcolepsy is a biological condition caused by a lack of orexin, not a lifestyle choice. Diagnosis involves measuring orexin levels in cerebrospinal fluid.

Classically activated (M1) macrophages reprogram their metabolism to favor aerobic glycolysis and lactate production over oxidative phosphorylation, leading to TCA cycle interruptions and accumulation of metabolites like citrate and succinate.

When immune cells fight acute threats, they switch to a fast, inefficient energy mode (glycolysis) that produces lactate and specific metabolites. This metabolic shift is a key part of the inflammatory response.

NOS1-expressing glutamatergic neurons in the preoptic area link thermal sensory information to NREM onset and body cooling.

This is a basic science finding explaining how warmth triggers sleep at the neural level. It confirms that sleep initiation is an active process driven by specific brain circuits responding to warmth, rather than a passive state.

Type 2 diabetes is a complex metabolic disorder driven by a strong genetic predisposition involving at least 75 identified common genetic loci, with heritability further modulated by epigenetic mechanisms such as DNA methylation in response to environmental factors.

Your risk for Type 2 Diabetes is significantly influenced by your genetics, with over 75 specific gene variants linked to the disease. However, this risk is not fixed; it interacts with your environment through epigenetic changes (like DNA methylation). This means that while you cannot change your DNA, you can influence how those genes are expressed through lifestyle factors, potentially mitigating genetic risk.

Sarcopenia should not be the sole criterion for declining or de-listing candidates for liver transplantation; it should be considered in the full context of other medical and psychosocial factors.

If you have sarcopenia, it does not automatically disqualify you from a liver transplant. It is a risk factor that your medical team will consider alongside your overall health. It may motivate your team to prioritize your case or consider different types of donor livers.

Greater height in young adulthood is inversely associated with the incidence of coronary heart disease and all types of stroke.

You cannot change your height, but this finding highlights the importance of early life health and socioeconomic factors. Focus on what you can control: maintaining a healthy weight and building muscle strength.

Supplementation with antioxidant vitamins (E, C, beta-carotene) fails to provide cardiovascular protection and may increase mortality or fatal CHD risk in large clinical trials.

Do not rely on high-dose antioxidant supplements (Vitamins E, C, Beta-Carotene) to prevent heart disease. Large clinical trials show they offer no benefit and may increase mortality risk. Focus on obtaining antioxidants from whole foods like fruits, vegetables, and whole grains instead.

Testosterone administration is absolutely contraindicated in men with clinical (metastatic) prostate cancer because androgen supplementation promotes tumor growth and progression.

If you have been diagnosed with metastatic prostate cancer, you must NOT take testosterone replacement therapy. It will cause your cancer to grow and spread. The standard treatment is to lower testosterone levels (androgen ablation).

Atherogenesis is fundamentally driven by the accumulation of oxidatively modified LDL in the arterial intima, facilitated by endothelial dysfunction and scavenger receptor uptake by macrophages to form foam cells.

High LDL cholesterol is a primary cause of atherosclerosis. The risk is highest when LDL is oxidized and taken up by macrophages to form foam cells. Managing LDL levels and reducing oxidative stress are key to preventing plaque buildup.

Gastrointestinal (GI) surgery is the only current treatment capable of achieving significant, long-term sustainable weight loss, primarily by altering the physiology and circulating levels of appetite-regulating gut hormones.

If you are struggling with obesity and other methods haven't provided lasting results, GI surgery is currently the only treatment proven to offer significant, long-term weight loss. This works by changing your gut hormones (like GLP-1 and PYY) to naturally reduce appetite. While surgery has risks and costs, it serves as the benchmark for what hormonal therapies aim to achieve safely.

There is no significant sex difference in the relative risk of cancer mortality associated with diabetes; the risk increase is comparable for both men and women.

While diabetes increases your risk of cancer, this relative increase is similar for both men and women. Focus on standard cancer screening and healthy lifestyle habits rather than worrying about a sex-specific cancer risk amplification from diabetes.

Self-reported sleep quality is NOT associated with neural health (white matter integrity) in healthy adults, despite associations in clinical populations.

Don't panic about occasional poor sleep causing permanent brain damage. This study found no link between self-reported sleep quality and white matter integrity in healthy adults. While clinical sleep disorders are serious, healthy sleep variations do not appear to harm brain structure.

Inhibition of IL-11 signaling through genetic deletion or therapeutic antibody administration extends mammalian healthspan and lifespan by mitigating age-associated metabolic decline, frailty, and tissue fibrosis.

This research suggests that targeting the IL-11 pathway could be a viable strategy for extending healthspan and lifespan in humans. While the study was conducted in mice, the findings support the potential of anti-IL-11 therapies, which are already in clinical trials for other conditions, to mitigate age-related decline. For now, this remains a preclinical finding, but it highlights IL-11 as a promising target for future longevity interventions.

LEAP2 acts as a GHSR antagonist that hyperpolarizes arcuate NPY neurons and prevents acyl-ghrelin from activating them, thereby blunting ghrelin's orexigenic effects.

This is a deep biological mechanism showing how your brain processes hunger signals. LEAP2 physically blocks the hunger signal at the neuronal level. This explains why high levels of LEAP2 in obesity might contribute to 'ghrelin resistance,' where the hunger signal is less effective.

Gestational diabetes is associated with increased risks of perinatal complications including hypertensive disorders, preterm delivery, shoulder dystocia, stillbirth, neonatal hypoglycemia, and cesarean delivery.

GDM increases the risk of several serious complications for both mother and baby, including high blood pressure, early delivery, difficult birth, and low blood sugar in the newborn. Proper management is crucial to mitigate these risks.